Nordin M J Hanssen1, Olaf Brouwers1, Marion J Gijbels2, Kristiaan Wouters1, Erwin Wijnands3, Jack P M Cleutjens3, Jo G De Mey4, Toshio Miyata5, Erik A Biessen3, Coen D A Stehouwer1, Casper G Schalkwijk6. 1. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands. 2. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands Department of Molecular Genetics, MUMC, Maastricht, The Netherlands Department of Medical Biochemistry, Amsterdam Medical Centre, Amsterdam, The Netherlands. 3. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands. 4. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark. 5. United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. 6. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands c.schalkwijk@maastrichtuniversity.nl.
Abstract
AIMS: Advanced glycation end-products (AGEs) and their precursors have been associated with the development of atherosclerosis. We recently discovered that glyoxalase 1 (GLO1), the major detoxifying enzyme for AGE precursors, is decreased in ruptured human plaques, and that levels of AGEs are higher in rupture-prone plaques. We here investigated whether overexpression of human GLO1 in ApoE(-/-) mice could reduce the development of atherosclerosis. METHODS AND RESULTS: We crossed C57BL/6 ApoE(-/-) mice with C57BL/6 GLO1 overexpressing mice (huGLO1(+/-)) to generate ApoE(-/-) (n = 16) and ApoE(-/-) huGLO1(+/-) (n = 20) mice. To induce diabetes, we injected a subset with streptozotocin (STZ) to generate diabetic ApoE(-/-) (n = 8) and ApoE(-/-) huGLO1(+/-) (n = 13) mice. All mice were fed chow and sacrificed at 25 weeks of age. The GLO1 activity was three-fold increased in huGLO1(+/-) aorta, but aortic root lesion size and phenotype did not differ between mice with and without huGLO1(+/-) overexpression. We detected no differences in gene expression in aortic arches, in AGE levels and cytokines, in circulating cells, and endothelial function between ApoE(-/-) mice with and without huGLO1(+/-) overexpression. Although diabetic mice showed decreased GLO1 expression (P < 0.05) and increased lesion size (P < 0.05) in comparison with non-diabetic mice, GLO1 overexpression also did not affect the aortic root lesion size or inflammation in diabetic mice. CONCLUSION: In ApoE(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation. Increasing GLO1 levels does not seem to be an effective strategy to reduce glycation in atherosclerotic lesions, likely due to increased AGE formation through GLO1-independent mechanisms. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Advanced glycation end-products (AGEs) and their precursors have been associated with the development of atherosclerosis. We recently discovered that glyoxalase 1 (GLO1), the major detoxifying enzyme for AGE precursors, is decreased in ruptured human plaques, and that levels of AGEs are higher in rupture-prone plaques. We here investigated whether overexpression of humanGLO1 in ApoE(-/-) mice could reduce the development of atherosclerosis. METHODS AND RESULTS: We crossed C57BL/6 ApoE(-/-) mice with C57BL/6 GLO1 overexpressing mice (huGLO1(+/-)) to generate ApoE(-/-) (n = 16) and ApoE(-/-) huGLO1(+/-) (n = 20) mice. To induce diabetes, we injected a subset with streptozotocin (STZ) to generate diabeticApoE(-/-) (n = 8) and ApoE(-/-) huGLO1(+/-) (n = 13) mice. All mice were fed chow and sacrificed at 25 weeks of age. The GLO1 activity was three-fold increased in huGLO1(+/-) aorta, but aortic root lesion size and phenotype did not differ between mice with and without huGLO1(+/-) overexpression. We detected no differences in gene expression in aortic arches, in AGE levels and cytokines, in circulating cells, and endothelial function between ApoE(-/-) mice with and without huGLO1(+/-) overexpression. Although diabeticmice showed decreased GLO1 expression (P < 0.05) and increased lesion size (P < 0.05) in comparison with non-diabeticmice, GLO1 overexpression also did not affect the aortic root lesion size or inflammation in diabeticmice. CONCLUSION: In ApoE(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation. Increasing GLO1 levels does not seem to be an effective strategy to reduce glycation in atherosclerotic lesions, likely due to increased AGE formation through GLO1-independent mechanisms. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Markus Wortmann; Maani Hakimi; Thomas Fleming; Andreas S Peters; Tjeerd P Sijmonsma; Stephan Herzig; Peter P Nawroth; Dittmar Böckler; Susanne Dihlmann Journal: J Diabetes Res Date: 2015-12-15 Impact factor: 4.011
Authors: Mitchell Bijnen; Nicky Beelen; Suzan Wetzels; José van de Gaar; Maria Vroomen; Erwin Wijnands; Jean L Scheijen; Marjo P H van de Waarenburg; Marion J Gijbels; Jack P Cleutjens; Erik A L Biessen; Coen D A Stehouwer; Casper G Schalkwijk; Kristiaan Wouters Journal: Sci Rep Date: 2018-10-15 Impact factor: 4.379
Authors: Jan Šilhavý; Hana Malínská; Martina Hüttl; Irena Marková; Olena Oliyarnyk; Petr Mlejnek; Miroslava Šimáková; František Liška; Ludmila Kazdová; Radka Moravcová; Jiří Novotný; Michal Pravenec Journal: Antioxidants (Basel) Date: 2020-11-26